An observational study in Alzheimers Disease, sponsored by Eisai Inc.. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Eisai Inc. · Observational
The primary purpose of this study is to evaluate the efficacy of LEQEMBI in participants with early Alzheimer's disease (AD) indicated per Canada Product Monograph (APOE4 non-carriers and heterozygotes; indicated population) compared with placebo (PBO)-treated participants from BAN2401-G000-301 (Study 301) Core study on change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment.
This is a non-interventional study using real-world retrospective efficacy (CDR-SB) data from prescribing institutions in North America to evaluate the efficacy of LEQEMBI.
As this is a Retrospective Database Study, the Study Start Date for this study references the date at which the first set of data will become available.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's planned enrollment of 270 is above the median of 200 across 751 observational studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Eisai Inc. is the lead sponsor of 361 studies on the registry; 8 are open to participants now.
Of its 81 completed or terminated interventional studies of FDA-regulated products, 54 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants with early Alzheimer's Disease treated with lecanemab will be observed retrospectively.
Exclusion Criteria:
Other: No Intervention
This is a non-interventional study.
Change from Baseline in the CDR-SB
Time frame: Baseline, 18 months
Time to Progression to the Next Stage of Alzheimer's Disease as Assessed by Global CDR Score
Time frame: Baseline, 18 months
Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eisai Inc.